Share Name Share Symbol Market Type Share ISIN Share Description
Convatec LSE:CTEC London Ordinary Share GB00BD3VFW73 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.30p -1.39% 162.80p 161.45p 161.80p 166.60p 158.95p 165.50p 5,260,764 16:35:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 1,306.5 121.4 5.9 26.0 3,177.00

Convatec Share Discussion Threads

Showing 301 to 324 of 325 messages
Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older
DateSubjectAuthorDiscuss
30/10/2018
09:55
Numis upgrades Convatec to ‘buy’ Numis has upgraded medical technology company Convatec (CTEC) after an ‘unwarranted’ 35% fall in the share price. Analyst Paul Cuddon upgraded his recommendation from ‘hold’ to ‘buy’ with a target price of 220p on the shares, which jumped 5.6% to 155p yesterday. ‘We do not think the loss of a chief executive and the decline in infusion devices warranted a 35% fall in Convatec’s share price, especially when the broader chronic care business is maintaining consistent 2% quarterly growth,’ he said. ‘We see full-year 2018 results, details on the self-help strategy and full-year 2019 outlook as key catalysts. The company trades on 10x enterprise value/earnings and offering sector leading free cashflow yield and so we upgrade to “buy”.’ HTTPS://citywire.co.uk/money/the-expert-view-just-eat-hsbc-and-iag/a1170201?re=59360&ea=290170&utm_source=BulkEmail_Money_Daily&utm_medium=BulkEmail_Money_Daily&utm_campaign=BulkEmail_Money_Daily#i=6
philanderer
26/10/2018
17:24
Detail.. Medical products and technologies company ConvaTec fell on Friday as UBS downgraded the stock to 'neutral' from 'buy' and slashed the target price to 150p from 250p, pointing to a slowdown in the wound market - to which the group is over-exposed - and limited progress in the ostomy turnaround. In addition, the bank highlighted concerns that EBIT margins will continue to decline, as investments are likely still required in internal controls, marketing and R&D, as well as capex. UBS said it expects just 2% group organic sales growth in all future periods. "We assume structural market share loss in Ostomy, with a 1% sales compound annual growth rate, ignoring significant investments aimed at delivering market growth of 5%. We also assume margins decline a further 100 basis points before stabilising at 22.5% from 2020, ignoring guidance of upside from 2020 from operating leverage and margin strategy to be announced in February 2019." In its upside scenario, UBS sees fair value at 240p a share. However, without a CEO and after high senior staff turnover since IPO, it's hard to get comfort execution issues won't continue, it said. Earlier this month, ConvaTec shares tumbled as it issued a profit and announced that CEO Paul Moraviec was stepping down. HTTPS://uk.webfg.com/news/broker-recommendations-/broker-tips-convatec-burberry--3562829.html
philanderer
26/10/2018
08:37
Downgrade from UBS 'neutral' from 'buy' ... TP 150p cut from 250p
philanderer
25/10/2018
08:56
Peel Hunt 'hold' tp 170p cut from 220p
philanderer
22/10/2018
10:34
ConvaTec Group, down 3.0%. HSBC downgraded the wound dressings maker to Hold from Buy. Target 165p cut from 245p
philanderer
19/10/2018
20:36
Thanks giardap.
erogenous jones
19/10/2018
20:18
You could get free samples from the other companies to try whilst running down your prescription. I need to declare I currently work for a UK manufacturer and 15 yrs ago used to work for ConvaTec R&D.
giardap
19/10/2018
18:49
Erogenous, get your Stoma Nurse to source alternative products for you to try. There are a number of manufacturers out there in the UK.
giardap
18/10/2018
20:15
I use their products. For the most part they provide dignity and a totally normal life. There are occasinal leaks, but fewer each year. This means that the product remains dynamic and evolving. So that you understand what I am wittering about, I have an ileostomy which is permanent and the product I use, is, I stress, a market leader. However, there have been difficulty in supply over the last 9 months. I gather that this has been addressed. In practice, the product that I have used for the last 10 years has been discontinued. Its replacement has been used for the last 3 weeks. It is unsatisfactory. A replacement is being investigated. Patients like advances that are beneficial not superficial. What is wrong with it? The closure system. Two catastrophic failures in as many weeks compared with one in the last 10 years.... co-incidence, perhaps?
erogenous jones
18/10/2018
19:53
Bought today at £1.49 - prepared to sit and wait.Ageing society - a good long term buy. Unfortunatately this company was "fleeced" prior to and ramped at IPO by PE owners. Hopefully as their influence dwindles ConvaTec can get on with running its business with more attention to detail.
giardap
18/10/2018
07:56
directors bought before the drop paying 220p ish a share
trjones2
16/10/2018
09:30
Director Buys - Finance Director yesterday and Senior Non Exec today - they are certainly very confident
nerdofsteel
16/10/2018
09:18
210p, 183p, 165p all greater than the current 155p at least
nerdofsteel
16/10/2018
08:47
Downgraded by JP Morgan Caz to 'neutral' ... tp 183p cut from 303p Downgraded by Goldmans to 'neutral' ... tp 165p cut from 255p
philanderer
16/10/2018
08:37
RBC retains 'outperform' ... target 210p cut from 240p
philanderer
16/10/2018
07:25
from Citywire Buying opportunity at Convatec, says Numis Medical technology company Convatec (CTEC) has delivered a poor third statement but the heavy share price fall could present a buying opportunity. The shares tumbled 34% to 148.2p yesterday after the company issued a profit warning and announced the departure of chief executive Paulk Moraviec. Analyst Paul Cuddon retained his ‘hold’ recommendation and target price of 220p on the shares. ‘Ultimately the statement reads poorly, but on our first take, the earnings per share downgrade is just 5% and should the shares fall materially we could see an interesting buying opportunity with the performance of the chronic care business showing continued steady growth,’ he said.
robow
16/10/2018
07:22
7% Free Cash Flow Yield. Bang on. Shorts can keep trying!
cantrememberthis2
15/10/2018
23:32
Lex Column: 'ConvaTec: scar issue' Medical products group needs more time to heal itself after investors were bloodied https://www.ft.com/content/07bc74d8-d04d-11e8-a9f2-7574db66bcd5
philanderer
15/10/2018
23:17
'ConvaTec shares plunge after profit warning and chief’s exit' Second profit warning in 12 months for medical equipment maker Analysts naming Medtronic as C'tecs biggest customer which has "changed it's ordering pattern of its infusion devices business" article: https://www.ft.com/content/672418a6-d041-11e8-a9f2-7574db66bcd5
philanderer
15/10/2018
20:05
Back on the watchlist . Numis... 'hold' tp 220p Peel Hunt ... 'hold'
philanderer
15/10/2018
19:56
From sharemagazine JP Morgan Cazenove analyst David Adlington is surprised by yet another profit warning following ‘positive commentary’ over the summer from management. He believes the new guidance implies a decline by 5% to 10% in earnings per share, but argues the valuation is still ‘attractive217; with ‘limited further downside’.
cantrememberthis2
15/10/2018
19:46
Despite the warning and its cautious stance on the stock, RBC said the share price reset has gone too far and highlighted the fact that Convatec is still a cash generative business with attractive qualities. "We would remind investors that Convatec is still a highly cash generative business, and at the current share price is generating a free cash flow yield of over 7%, with a dividend yield of 3%," it said. "With the performance wanting we would hope all options are now on the table to maximise shareholder value."
cantrememberthis2
15/10/2018
13:39
NICE - Fast reactions, even a bean counter is parting with their money at 150p/share. Game on dudes. Shorts may close, well come of them. Some DIRECTORS wait days, these boys are doing it like MICROFOCUS...so quickly.
cantrememberthis2
15/10/2018
13:36
Director Buying
nerdofsteel
Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20181116 01:45:34